Research programme: anticancer therapeutics - Affichem

Drug Profile

Research programme: anticancer therapeutics - Affichem

Alternative Names: AF 122; AF300; AFF 354; DDA; Dendrogenin A

Latest Information Update: 11 Jul 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator AFFICHEM
  • Developer Affichem
  • Class Small molecules; Sterols
  • Mechanism of Action Cell differentiation stimulants; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Breast cancer; Leukaemia; Malignant melanoma
  • No development reported Cancer; Colorectal cancer

Most Recent Events

  • 11 Jul 2018 AF 122 is still in preclinical trials for Leukaemia, Malignant melanoma and Breast cancer in France (Affichem pipeline, July 2018)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in France
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Colorectal-cancer in France
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top